FDA Clears Gene Therapy Trial for Phenylketonuria (PKU)

SentiSense · Published · Updated

Beam Therapeutics has received FDA clearance to begin a clinical trial for its BEAM-304 base-editing gene therapy targeting phenylketonuria (PKU), whi...

Sign in to read the full story. Free accounts include 20 full reads a month.

Sign in or create a free account

Powered by SentiSense - Intelligent Market Analysis